Immunovia AB ( (IMMVF) ) has released its Q2 earnings. Here is a breakdown of the information Immunovia AB presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB, a company specializing in the early detection of pancreatic cancer through innovative diagnostic solutions, has released its earnings report for the second quarter of 2025. The company is on the verge of launching its PancreaSure test, a next-generation blood-based diagnostic tool for early pancreatic cancer detection, marking a significant milestone in its commercial journey.
During the April to June 2025 period, Immunovia reported a slight increase in net sales to 90 TSEK, primarily from royalties, compared to 85 TSEK in the same period last year. However, the company faced a net loss of 41.1 MSEK, attributed mainly to unrealized currency effects due to a weaker dollar impacting transactions for its U.S. operations. Despite the financial challenges, the company managed to reduce its cash burn rate and improved cash flow from operations compared to the previous year.
A key highlight for Immunovia is the upcoming commercial launch of the PancreaSure test in the U.S., scheduled for September 2, 2025. This test has received strong support from leading experts and will be integrated into high-risk monitoring programs at several prominent medical centers. The company has also made significant progress in securing coverage and reimbursement, including obtaining a CPT code necessary for Medicare claims.
Looking ahead, Immunovia plans to conduct a rights issue to raise up to 100 MSEK, which will support the PancreaSure launch and further clinical studies. The company’s management remains optimistic about achieving key milestones in commercializing PancreaSure and securing reimbursement, which are crucial for its financial stability and growth.